Acute promyelocytic leukaemia in a patient treated with etoposide for Langerhans cell histiocytosis

A. Matsuzaki, T. Inamitsu, T. Watanabe, Shoichi Ohga, E. Ishii, Y. Nagotoshi, H. Tasaka, M. Suda, K. Ueda

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We report a child with acute promyelocytic leukaemia (APL) who was treated with etoposide (VP16) for Langerhans cell histiocytosis (LCH). A 3-year-old Japanese girl was diagnosed as having LCH. She was treated with combination chemotherapy using VP16 and prednisolone. 56 months after beginning the chemotherapy she developed APL. Her bone marrow was occupied with atypical promyelocytes including giant granules and multiple Auer bodies. A cytogenetic analysis of the leukaemic cells showed 46,XX,11p-,14q+,t(15,17). The cumulative dose of the administered VP16 was 12120 mg/m2, which suggested that VP16 may be responsible for the development of APL. The risk of developing secondary leukaemia after the administration of VP16 should therefore be considered when managing patients with LCH.

Original languageEnglish
Pages (from-to)887-889
Number of pages3
JournalBritish Journal of Haematology
Volume86
Issue number4
DOIs
Publication statusPublished - Jan 1 1994

Fingerprint

Langerhans Cell Histiocytosis
Acute Promyelocytic Leukemia
Etoposide
Granulocyte Precursor Cells
Cytogenetic Analysis
Prednisolone
Combination Drug Therapy
Leukemia
Bone Marrow
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Acute promyelocytic leukaemia in a patient treated with etoposide for Langerhans cell histiocytosis. / Matsuzaki, A.; Inamitsu, T.; Watanabe, T.; Ohga, Shoichi; Ishii, E.; Nagotoshi, Y.; Tasaka, H.; Suda, M.; Ueda, K.

In: British Journal of Haematology, Vol. 86, No. 4, 01.01.1994, p. 887-889.

Research output: Contribution to journalArticle

Matsuzaki, A, Inamitsu, T, Watanabe, T, Ohga, S, Ishii, E, Nagotoshi, Y, Tasaka, H, Suda, M & Ueda, K 1994, 'Acute promyelocytic leukaemia in a patient treated with etoposide for Langerhans cell histiocytosis', British Journal of Haematology, vol. 86, no. 4, pp. 887-889. https://doi.org/10.1111/j.1365-2141.1994.tb04851.x
Matsuzaki, A. ; Inamitsu, T. ; Watanabe, T. ; Ohga, Shoichi ; Ishii, E. ; Nagotoshi, Y. ; Tasaka, H. ; Suda, M. ; Ueda, K. / Acute promyelocytic leukaemia in a patient treated with etoposide for Langerhans cell histiocytosis. In: British Journal of Haematology. 1994 ; Vol. 86, No. 4. pp. 887-889.
@article{a03a5b797efb4dfda0196ca1dc33b8e3,
title = "Acute promyelocytic leukaemia in a patient treated with etoposide for Langerhans cell histiocytosis",
abstract = "We report a child with acute promyelocytic leukaemia (APL) who was treated with etoposide (VP16) for Langerhans cell histiocytosis (LCH). A 3-year-old Japanese girl was diagnosed as having LCH. She was treated with combination chemotherapy using VP16 and prednisolone. 56 months after beginning the chemotherapy she developed APL. Her bone marrow was occupied with atypical promyelocytes including giant granules and multiple Auer bodies. A cytogenetic analysis of the leukaemic cells showed 46,XX,11p-,14q+,t(15,17). The cumulative dose of the administered VP16 was 12120 mg/m2, which suggested that VP16 may be responsible for the development of APL. The risk of developing secondary leukaemia after the administration of VP16 should therefore be considered when managing patients with LCH.",
author = "A. Matsuzaki and T. Inamitsu and T. Watanabe and Shoichi Ohga and E. Ishii and Y. Nagotoshi and H. Tasaka and M. Suda and K. Ueda",
year = "1994",
month = "1",
day = "1",
doi = "10.1111/j.1365-2141.1994.tb04851.x",
language = "English",
volume = "86",
pages = "887--889",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Acute promyelocytic leukaemia in a patient treated with etoposide for Langerhans cell histiocytosis

AU - Matsuzaki, A.

AU - Inamitsu, T.

AU - Watanabe, T.

AU - Ohga, Shoichi

AU - Ishii, E.

AU - Nagotoshi, Y.

AU - Tasaka, H.

AU - Suda, M.

AU - Ueda, K.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We report a child with acute promyelocytic leukaemia (APL) who was treated with etoposide (VP16) for Langerhans cell histiocytosis (LCH). A 3-year-old Japanese girl was diagnosed as having LCH. She was treated with combination chemotherapy using VP16 and prednisolone. 56 months after beginning the chemotherapy she developed APL. Her bone marrow was occupied with atypical promyelocytes including giant granules and multiple Auer bodies. A cytogenetic analysis of the leukaemic cells showed 46,XX,11p-,14q+,t(15,17). The cumulative dose of the administered VP16 was 12120 mg/m2, which suggested that VP16 may be responsible for the development of APL. The risk of developing secondary leukaemia after the administration of VP16 should therefore be considered when managing patients with LCH.

AB - We report a child with acute promyelocytic leukaemia (APL) who was treated with etoposide (VP16) for Langerhans cell histiocytosis (LCH). A 3-year-old Japanese girl was diagnosed as having LCH. She was treated with combination chemotherapy using VP16 and prednisolone. 56 months after beginning the chemotherapy she developed APL. Her bone marrow was occupied with atypical promyelocytes including giant granules and multiple Auer bodies. A cytogenetic analysis of the leukaemic cells showed 46,XX,11p-,14q+,t(15,17). The cumulative dose of the administered VP16 was 12120 mg/m2, which suggested that VP16 may be responsible for the development of APL. The risk of developing secondary leukaemia after the administration of VP16 should therefore be considered when managing patients with LCH.

UR - http://www.scopus.com/inward/record.url?scp=0028229192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028229192&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.1994.tb04851.x

DO - 10.1111/j.1365-2141.1994.tb04851.x

M3 - Article

C2 - 7918090

AN - SCOPUS:0028229192

VL - 86

SP - 887

EP - 889

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -